Planet 13 Holdings Inc.

CNSX:PLTH Stock Report

Market Cap: CA$195.1m

Planet 13 Holdings Valuation

Is PLTH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PLTH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PLTH's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PLTH's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PLTH?

Key metric: As PLTH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PLTH. This is calculated by dividing PLTH's market cap by their current revenue.
What is PLTH's PS Ratio?
PS Ratio1.2x
SalesUS$109.09m
Market CapUS$139.55m

Price to Sales Ratio vs Peers

How does PLTH's PS Ratio compare to its peers?

The above table shows the PS ratio for PLTH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.2x
OGI Organigram Holdings
1.5x16.5%CA$220.4m
CPH Cipher Pharmaceuticals
10.2x18.8%CA$374.9m
ACB Aurora Cannabis
1.1x11.8%CA$319.7m
RX BioSyent
3.9x12.0%CA$126.5m
PLTH Planet 13 Holdings
1.2x41.2%CA$195.1m

Price-To-Sales vs Peers: PLTH is good value based on its Price-To-Sales Ratio (1.2x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does PLTH's PS Ratio compare vs other companies in the CA Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
AYR.A Ayr Wellness
0.2x2.6%US$82.27m
ACRG.A.U Acreage Holdings
0.08xn/aUS$26.82m
MRV Nuvo Pharmaceuticals
0.2xn/aUS$11.21m
IMCC IM Cannabis
0.2x24.8%US$7.96m
PLTH 1.2xIndustry Avg. 0.7xNo. of Companies23PS012345+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: PLTH is expensive based on its Price-To-Sales Ratio (1.2x) compared to the Canadian Pharmaceuticals industry average (0.7x).

Price to Sales Ratio vs Fair Ratio

What is PLTH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PLTH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.2x
Fair PS Ratio3.1x

Price-To-Sales vs Fair Ratio: PLTH is good value based on its Price-To-Sales Ratio (1.2x) compared to the estimated Fair Price-To-Sales Ratio (3.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PLTH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCA$0.57
CA$1.49
+161.1%
36.2%CA$2.03CA$0.95n/a2
Nov ’25CA$0.77
CA$1.61
+109.5%
25.6%CA$2.03CA$1.20n/a2
Oct ’25CA$0.79
CA$1.60
+102.5%
25.0%CA$2.00CA$1.20n/a2
Sep ’25CA$0.75
CA$1.60
+113.3%
25.0%CA$2.00CA$1.20n/a2
Aug ’25CA$0.62
CA$1.61
+160.2%
25.6%CA$2.03CA$1.20n/a2
Jul ’25CA$0.65
CA$1.60
+146.6%
25.4%CA$2.01CA$1.20n/a2
Feb ’25CA$1.07
CA$1.72
+61.2%
16.3%CA$2.01CA$1.44n/a2
Jan ’25CA$0.86
CA$1.72
+100.5%
16.3%CA$2.01CA$1.44n/a2
Dec ’24CA$1.02
CA$1.72
+69.1%
16.3%CA$2.01CA$1.44n/a2
Nov ’24CA$0.84
CA$1.71
+103.2%
17.0%CA$2.00CA$1.42CA$0.772
Oct ’24CA$1.17
CA$1.71
+45.9%
17.0%CA$2.00CA$1.42CA$0.792
Sep ’24CA$1.19
CA$1.71
+43.4%
17.0%CA$2.00CA$1.42CA$0.752
Aug ’24CA$0.78
CA$1.67
+114.1%
16.2%CA$1.94CA$1.40CA$0.622
Jul ’24CA$0.76
CA$1.68
+121.4%
16.9%CA$1.97CA$1.40CA$0.652
Jun ’24CA$0.77
CA$1.68
+118.6%
16.9%CA$1.97CA$1.40CA$0.792
May ’24CA$0.93
CA$1.69
+81.6%
17.1%CA$1.98CA$1.40CA$0.892
Apr ’24CA$1.05
CA$1.70
+61.6%
17.5%CA$1.99CA$1.40CA$0.892
Mar ’24CA$1.15
CA$2.10
+82.4%
33.4%CA$2.80CA$1.40CA$1.022
Feb ’24CA$1.20
CA$2.13
+77.6%
29.5%CA$2.76CA$1.50CA$1.072
Jan ’24CA$0.83
CA$2.13
+156.7%
29.5%CA$2.76CA$1.50CA$0.862
Dec ’23CA$1.86
CA$2.13
+14.6%
29.5%CA$2.76CA$1.50CA$1.022
Nov ’23CA$1.74
CA$2.45
+41.0%
29.0%CA$3.17CA$1.74CA$0.842

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Fennec Pharmaceuticals

US$117.3m

Operates as a biopharmaceutical company in the United States.

FRX

US$6.50

7D

7.6%

1Y

-44.2%

Medexus Pharmaceuticals

CA$52.0m

Operates as a pharmaceutical company in Canada and the United States.

MDP

CA$2.15

7D

5.4%

1Y

40.5%

Verano Holdings

CA$850.9m

Operates as a vertically integrated multi-state cannabis operator in the United States.

VRNO

CA$2.32

7D

-12.8%

1Y

-60.6%